This segment examines the decision-making process between CAR-T therapy and other innovative treatments, exploring scenarios where alternative therapies may be more appropriate.
Video content above is prompted by the following:
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.